Literature DB >> 1030780

Spontaneous regression of hematologic cancers.

P H Wiernik.   

Abstract

Spontaneous regression of hematologic cancer is extremely rare. Data gleaned from the literature and from previously unreported cases allow certain interesting general conclusions. Spontaneous remission of acute leukemia is associated with bacterial infection and is of short duration, weeks to months. Spontaneous regression of lymphoma or plasma cell dyscrasia is often of substantial duration, months or years, and frequently is associated with viral infections. Spontaneous regression of chronic lymphocytic leukemia is also of significant duration and has been associated with the occurence of a new primary carcinoma in one-third of the cases.

Entities:  

Mesh:

Year:  1976        PMID: 1030780

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  15 in total

1.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

2.  Clinical significance of natural killing activity in patients with advanced lymphoma.

Authors:  K Ono
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

3.  Spontaneous regression of pancreatic cancer with liver metastases.

Authors:  Patricia Saade Lemus; Kevin Anderson; Martin Smith; Andrea Bullock
Journal:  BMJ Case Rep       Date:  2019-05-31

Review 4.  Cardiac lymphoma with early response to chemotherapy: A case report and review of the literature.

Authors:  Andrea Bonelli; Sara Paris; Stefano Bisegna; Giuseppe Milesi; Emanuele Gavazzi; Raffaele Giubbini; Chiara Cattaneo; Fabio Facchetti; Pompilio Faggiano
Journal:  J Nucl Cardiol       Date:  2021-03-11       Impact factor: 5.952

5.  Natural killing activity in patients with spontaneous regression of malignant lymphoma.

Authors:  K Ono; M Kikuchi; N Funai; M Matsuzaki; Y Shimamoto
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

6.  Leukemic progression as process of adaptation (theoretical model).

Authors:  I V Alekseyev
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

7.  Complete regression of myocardial involvement associated with lymphoma following chemotherapy.

Authors:  Juan Pablo Vinicki; Tomás F Cianciulli; Gustavo A Farace; María C Saccheri; Jorge A Lax; Lucía R Kazelian; Adolfo Wachs
Journal:  World J Cardiol       Date:  2013-09-26

8.  Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas.

Authors:  D Cunningham; N L Gilchrist; R A Cowan; G J Forrest; C S McArdle; M Soukop
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

9.  Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.

Authors:  V Raina; D Cunningham; N Gilchrist; M Soukop
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

Review 10.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.